The effects of inhaled nitric oxide, gabexate mesilate, and retrograde flush in the lung graft from non-heart beating minipig donors

Transplantation

Volumn 69, Issue 10, 2000, Pages 2019-2027

  Luh, Shi Ping ^a   Tsai, Chien Chen ^a   Shau, Wen Yi ^a   Chen, Jin Shin ^a   Kuo, Sow Hsong ^a   Lin Shiau, Shoei Yn ^a   Lee, Yung Chie ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EURO COLLINS SOLUTION; GABEXATE MESILATE; HEPARIN; NITRIC OXIDE; PROSTAGLANDIN E1; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; GAS EXCHANGE; HEART ARREST; LUNG ARTERY PRESSURE; LUNG COMPLIANCE; LUNG INJURY; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; REPERFUSION; SCORING SYSTEM; SWINE;

EID: 0034720612     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200005270-00008     Document Type: Article

References (39)

1. Van Raemdonck D, Roels L, Verleden G, et al. Whence the lungs: assessment of the use of lungs for transplantation from 156 consecutive donors. In: Cooper JD, Weder W, eds. Proceedings of the Third International Lung Transplant Symposium (Zurich, Switzerland, June 24-25, 1993). 1993; 40.
2. Couetil JPA, Tolan MJ, Loulmet DF, et al. Pulmonary bipartitioning and lobar transplantation: a new approach to donor organ shortage. J Thorac Cardiovasc Surg 1997; 113: 529.
3. Starnes VA, Barr ML, Cohen RG, et al. Living-donor lobar lung transplantation experience: international results. J Thorac Cardiovasc Surg 1996; 112: 1284.
4. Egan TM, Lambert CJ Jr, Reddick R, Ulicny KS Jr, Keagy BA, Wilcox BR. A strategy to increase the donor pool: use of cadaver lungs for transplantation. Ann Thorac Surg 1991; 52: 1113.
5. D'Armini AM, Roberts CS, Griffith PK, Lemasters JJ, Egan TM. When does the lung die? I. Histochemical evidence of pulmonary viability after "death." J Heart Lung Transplant 1994; 13: 741.
6. Singh S, TW Evans. Nitric oxide, the biological mediator of the decade: fact or fiction? Eur Respir J 1997; 10: 699.
7. Kuo PC, Schroeder RA. The emerging multifaceted roles of nitric oxide. Ann Surg 1995; 221: 220.
8. Cooke JP, Tsao PS. Cytoprotective effect of nitric oxide. Circulation 1993; 88: 2451.
9. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1995; 88: 4651.
10. Murakami K, Okajima K, Uchiba M, Okabe H, Takatsuki K. Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes. Crit Care Med 1996; 24: 1047.
11. Niehaus GD, Kimura R, Traber LD, et al. Administration of a synthetic antiprotease reduces smoke-induced lung injury. J Appl Physiol 1990; 69: 694.
12. Umemori Y, Date H, Uno K, Aoe M, Ando A, Shimizu N. Improved lung function by urokinase infusion in the lung transplantation using non-heart-beating donors. Ann Thorac Surg 1995; 59: 1513.
13. Date H, Matsumura A, Manchester JK, et al. Evaluation of lung metabolism during successful twenty-four-hour canine lung preservation. J Thorac Cardiovasc Surg 1993; 105: 480.
14. Nakayama M, Hasegawa N, Oka Y, et al. Effects of the lazaroid, titrilazad mesylate, on sepsis-induced acute lung injury in minipigs. Crit Care Med 1998; 26: 538.
15. Nishing K. Inhaled nitric oxide does not prevent endotoxin induced lung injury in rabbits. Ann Anes Scand 1997; 41: 399.
16. Friedman M, Selike FW, Steven Y, et al. Parameters of pulmonary injury after total or partial cardiopulmonary bypass. Circulation 1994; 90: 262.
17. Goldlum SE, Wu K, Jay M. Lung myeloperoxidase as a measure of pulmonary leukostasis in rabbits. J Appl Physiol 1985; 59: 1978.
18. Kraiwsz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity: assessment of inflammation in rat and hamster models. Gastroenterology 1984; 87: 1344.
19. Lechner JF, Stoner GD, Yoakum GH, et al. In vitro carcinogenesis studies with human tracheobronchial tissues and cells. In: Schiff LJ ed. In vitro models of respiratory epithelium. Boca Raton, FL: CRC Press, 1986.
20. Alessandrini F, D'Armini AM, Robberts CS, Reddick RL, Egan TM. When does the lung die? II. Ultrastructural evidence of pulmonary viability after "death." J Heart Lung Transplant 1994; 13: 748.
21. Ulicny KS Jr, Egan TM, Lambert CJ Jr, Reddick RL, Wilcox BR. Cadaver lung donors: effect of preharvest ventilation on graft function. Ann Thorac Surg 1993; 55: 1185.
22. Roberts CS, D'Armini AM, Egan TM. Canine double-lung transplantation with cadaveric donors. J Thorac Cardiovasc Surg 1996; 112: 577.
23. Bacha EA, Sellak H, Murakami S, et al. Inhaled nitric oxide attenuates reperfusion injury in non-heart beating donor lung transplantation. Transplantation 1997; 63: 1380.
24. Roberts CS, Hennington MH, D'Armini AM, Griffith PK, Lemasters JJ, Egan TM. Donor lungs from ventilated cadavers: impact of a free radical scavenger. J Heart Lung Transplant 1996; 15: 275.
25. Ulicny KS Jr, Egan TM, Lambert CJ Jr, Reddick RL, Wilcox BR. Cadaver lung donors: effect of preharvest ventilation on graft function. Ann Thorac Surg 1993; 55: 1185.
26. Van Raemdonck D, Jannis N, Rega F, De Leyn P, Flameng WJ, Lerut TE. Extended preservation of ischemic pulmonary graft by postmortem alveolar expansion. Ann Thorac Surg 1997; 64: 801.
27. Higgins RSD, Sanchez JA, Lorber, MI, Baldwin JC. The multiorgan donor. Maldon, MA: Blackwell Science, 1997: 169.
28. LoCicero J III, Massad M, Oba J, Greene R, de Tarnowsky J Extended lung preservation by bronchial artery perfusion with University of Wisconsin solution. Transplant Proc 1991; 23: 670.
29. LoCicero J III, Massad M, Matano J, Greene R, Dunn M, Michaelis LL. Contribution of the bronchial circulation to lung preservation. J Thorac Cardiovasc Surg 1991; 101: 807.
30. Sarsam MA, Yonan NA, Deiraniya AK, Rahman AN. Retrograde pulmonaryplegia for lung preservation in clinical transplantation: a new technique. J Heart Lung Transplant 1993; 12: 498.
31. Chen CA, Gallagher RC, Ardery P, Dyckman W, Low HBC. Retrograde versus antegrade flush in canine lung preservation for six hours. J Heart Lung Transplant 1996; 15: 395.
32. Bacha EA, Herve P, Murakami S, et al. Lasting beneficial effect of short term inhaled nitric oxide on graft function after lung transplantation. J Thorac Cardiovasc Surg 1995; 112: 590.
33. Lindberg L, Sjoberg T, Ingemansson R, Steen S. Inhalation of nitric oxide after lung transplantation. Ann Thorac Surg 1996; 61: 956.
34. Murakami S, Bacha EA, Herve P, et al. Prevention of reperfusion injury by inhaled nitric oxide in lungs harvested from non-heart-beating donors. Ann Thorac Surg 1996; 62: 1632.
35. Pederzoli P, Cavallini G, Falconi M, et al. Gabexate mesilate versus aprotinin in human acute pancreatitis. Int J Pancreatol 1993; 14: 117.
36. Taeneka N, Shimada Y, Hirata T, et al. Gabexate mesilate (FOY) therapy of disseminated intravascular coagulation due to sepsis. Crit Care Med 1983; 11: 735.
37. Nishijima J, Hiraoka N, Murata A, et al. Protease inhibitors (gabexate mesilate and ulnastatin) inhibit intracellular chemiluminescence in human neutrophils. J Leukoc Biol 1992; 52: 262.
38. Tamura K, Manabe T, Imanishi K, et al. Effect of synthetic protease inhibitors on superoxide, hydrogen peroxide, and hydroxyl radical production by human polymorphonuclear leukocytes. Hepatogastroenterology 1992; 39: 59.
39. Luh SP, Tsai CC, Shau WY, et al. Effects of the Gabexate mesilate (FOY) on ischemia-reperfusion induced acute lung injury in dogs. J Surg Research (in press).